Delivering more actionable and strategically valuable research, The Business Research Company’s 2026 market reports feature market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights.

Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market Growth Analysis: How Will Revenue Expand During The Forecast Period?

The market size for metabolic dysfunction-associated steatohepatitis (MASH) treatments has experienced significant growth in recent years. This market is projected to expand from $3.18 billion in 2025 to $3.88 billion in 2026, achieving a compound annual growth rate (CAGR) of 22.2%. Historically, this expansion has been driven by factors such as the increasing prevalence of obesity, a rise in the incidence of type 2 diabetes, heightened awareness regarding liver health disorders, advancements in diagnostic testing capabilities, and the early adoption of lifestyle modification programs.

The metabolic dysfunction-associated steatohepatitis (mash) treatment market size is projected to experience substantial expansion in the coming years. It is forecast to attain $8.6 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 22.0%. The anticipated growth during this period is primarily driven by the increasing integration of GLP-1 agonists, advancements in antifibrotic drug development, the rising adoption of digital liver monitoring tools, broader application of bariatric surgery, and an increased emphasis on personalized metabolic therapies. Key developments expected in the forecast period include the expansion of precision liver disease therapeutics, AI-enabled capabilities for early detection and risk stratification, cloud-based systems for liver health data management, IoT-integrated solutions for lifestyle and medication monitoring, and the growth of sustainable and preventive metabolic health initiatives.

Download A Free Sample Report For Comprehensive Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=20876&type=smp

Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market Expansion Supported By Key Demand Factors

The rising occurrence of obesity is set to advance the metabolic dysfunction-associated steatohepatitis (MASH) treatment market moving forward. Obesity is a medical state marked by an excessive build-up of body fat that can negatively affect overall well-being, typically measured by a body mass index (BMI) of 30 or above. The global prevalence of obesity is increasing, fueled by inactive lifestyles, poor diets, and metabolic risk factors. Metabolic Dysfunction-Associated Steatohepatitis (MASH) treatment when associated with obesity aims at addressing insulin resistance, lowering liver fat, and improving metabolic health through lifestyle adjustments and specific therapies. For example, in March 2023, the World Heart Foundation, a Switzerland-based non-governmental global cardiovascular community, reported that around 2.3 billion adults and children worldwide are presently obese or overweight, and this figure is anticipated to reach 2.7 billion by 2025, given the ongoing obesity trend. Hence, the growing prevalence of obesity is propelling expansion within the metabolic dysfunction-associated steatohepatitis (MASH) treatment market.

Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market Segment Landscape And Growth Potential

The metabolic dysfunction-associated steatohepatitis (mash) treatment market covered in this report is segmented –

1) By Treatment: Drug, Therapy

2) By Distribution Channel: Hospital Pharmacies, Online Pharmacies, Retail Pharmacies

3) By End-User: Hospitals, Specialty Clinics, Homecare, Other End-User

Subsegments:

1) By Drug: Antifibrotic Agents, Antidiabetic Drugs, Lipid-Lowering Agents, Vitamin E, Obeticholic Acid (OCA), GLP-1 Agonists

2) By Therapy: Pharmacotherapy, Lifestyle Modifications (Dietary Changes, Exercise), Bariatric Surgery, Liver Transplantation

Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market Growth Trends Influencing Competitive Dynamics

Major companies within the metabolic dysfunction-associated steatohepatitis (MASH) treatment market are concentrating on developing innovative products like liver fibrosis treatment solutions to offer therapeutic choices for individuals with metabolic dysfunction-associated steatohepatitis (MASH) and moderate to severe liver fibrosis. These liver fibrosis treatment solutions aim to address the fundamental causes of liver damage through lifestyle adjustments, antiviral medications, and evolving antifibrotic therapies, with the objective of halting or reversing fibrosis progression and enhancing liver function. For instance, in March 2024, Madrigal Pharmaceuticals, Inc., a US-based biopharmaceutical company, announced the FDA approval of Rezdiffra (resmetirom), which is the first-ever treatment for metabolic dysfunction-associated steatohepatitis (MASH) accompanied by moderate to severe liver fibrosis. Rezdiffra, a daily oral tablet, demonstrated effectiveness in resolving MASH without exacerbating fibrosis and in improving liver fibrosis during phase 3 clinical trials. This breakthrough provides a non-invasive treatment option, eliminating the necessity for liver biopsies, and considerably improves patient access and outcomes in the management of fatty liver disease.

Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market Competitive Landscape: Who Are The Leading Companies?

Major companies operating in the metabolic dysfunction-associated steatohepatitis (mash) treatment market are Pfizer Inc., Johnson & Johnson, Merck & Co. Inc., Sanofi SA, AstraZeneca PLC, Novartis AG, Eli Lilly and Company, Gilead Sciences Inc., Boehringer Ingelheim International GmbH, Novo Nordisk A/S, Apollo Health and Lifestyle Limited, Jenny Craig, Nutrisystem, Madrigal Pharmaceuticals, Anoos Clinic, Galectin Therapeutics Inc., Galmed Pharmaceuticals, Hepion Pharmaceuticals, Inventiva, NGM Biopharmaceuticals, Sagimet Biosciences, Viking Therapeutics, Terns Pharma, Genfit SA

Access The Complete Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market Report:

https://www.thebusinessresearchcompany.com/report/metabolic-dysfunction-associated-steatohepatitis-mash-treatment-global-market-report

Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market Regional Distribution: Which Areas Drive Market Expansion?

North Americawas the largest region in the metabolic dysfunction-associated steatohepatitis (MASH) treatment market in 2025. Asia-Pacificis expected to be the fastest-growing region in the forecast period. The regions covered in the metabolic dysfunction-associated steatohepatitis (mash) treatment market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas: +1 310-496-7795

Asia: +44 7882 955267 & +91 8897263534

Europe: +44 7882 955267

Email us at: marketing@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

[KClientError] [REQ_ERR: OPERATION_TIMEDOUT] [KTrafficClient] Something is wrong.